ReviewEuropean journal of neurology2024
Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.
Review in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Neuro-immune interactions in tumors, immune-related disorders, and infections.Signal transduction and targeted therapy · 2026Review
- Autonomic Dysfunction After Guillain-Barré Syndrome: Evidence from Comprehensive Autonomic Testing.Journal of clinical medicine · 2026Article
- U1 Small Nuclear Ribonucleoprotein Autoantibodies Reflect the Disruption of the Blood-Nerve Barrier in Guillain-Barré Syndrome.International journal of molecular sciences · 2026Article
- Human parvovirus B19-associated Guillain-Barré syndrome diagnosed by cerebrospinal fluid targeted next-generation sequencing: a case report and literature review.BMC infectious diseases · 2026Review
- The EGR1/ZFP36 axis governs glycosphingolipid metabolic reprogramming in monocyte-derived macrophages in guillain-barré syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- α2-3-sialylated glycosphingolipids in neuroinflammation, immunity, and programmed cell death: mechanistic evidence and context-dependent regulation: a comprehensive review.Frontiers in immunology · 2026Review
- Case Report: Guillain-Barré syndrome mimicking acute brainstem stroke with severe autonomic dysfunction-complete recovery after early plasma exchange.Frontiers in physiology · 2026Article
- Malnutrition, contaminated water, and post-infectious neuropathies: lessons from the Guillain-Barré syndrome outbreak in Gaza.Annals of medicine and surgery (2012) · 2026Article
- Efgartigimod for Guillain-Barré syndrome: rationale, clinical evidence, and future perspectives.Frontiers in immunology · 2026Review
- Clinical outcomes and safety of efgartigimod in Guillain-Barré syndrome: a retrospective observation study.Frontiers in immunology · 2026Observational
- Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety.Therapeutic advances in neurological disorders · 2026Article
- Peripheral blood T-cell subsets combined with EGRIS score predict the need for mechanical ventilation in Guillain-Barré syndrome.Frontiers in immunology · 2026Article
- The Neuroprotective Effect of 4-Octyl Itaconate on Acute Period of Experimental Autoimmune Neuritis.Inflammation · 2025Article
- Nephrotic syndrome and Guillain-Barré syndrome following umbilical cord blood transplantation in acute myeloid leukemia: correlated with COVID-19?BMC infectious diseases · 2025Article
- Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome.Orphanet journal of rare diseases · 2025Article
- Fatal recurrent Guillain-Barré syndrome (GBS) in an Ethiopian male: a case report.Journal of medical case reports · 2025Article
- Article
- Efgartigimod for treating Guillain-Barré syndrome with poor response to intravenous immunoglobulin: a case report.BMC neurology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeSince its description by Guillain, Barré, and Strohl in 1916, Guillain-Barré syndrome (GBS) has attracted a large literature. The author reviews the history of research into its pathogenesis and treatment to highlight promising avenues for future research.
methodsThis is a nonsystematic personal review.
resultsSince the early 1900s, the clinical picture of GBS has been illustrated in multiple series culminating in the ongoing International Guillain-Barré Syndrome study of 2000 patients. In the 1950s and 1960s, the inflammatory nature of the commonest form, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), was described. In the 1990s, two axonal forms, acute motor-sensory axonal neuropathy and acute motor axonal neuropathy, were recognized. In the 1990s and early 2000s, these forms were shown to be due to antibodies against Campylobacter jejuni glycans cross-reacting with glycolipids on axonal membranes. The pathogenesis of AIDP remains unknown, but T-cell responses to the compact myelin proteins, P2 and P0, which cause experimental autoimmune neuritis, suggest that T cells are important. Randomized controlled trials in the 1970s and 1980s showed no benefit from corticosteroids. Trials in the 1980s showed benefit from plasma exchange and in the 1990s from intravenous immunoglobulin.
conclusionsFuture research should seek biomarkers to identify subgroups with different treatment responses, define the true natural history of the disease with population-based epidemiological studies, study the pathology in autopsies early in the disease, seek causative antibodies and confirm autoimmune T-cell responses in AIDP, and expand treatment trials to include anti-T-cell agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.